MIND4-17 |
| Catalog No.GC70520 |
MIND4-17 est un puissant activateur de nrf2 qui modifie de manière covalente le résidu c151 de keap1.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 345989-24-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
MIND4-17 (0.1-2 μM; 24 hr) significantly and concentration-dependently increases the expression of the canonical ARE genes Nqo1, Hmox1, Srx1, and to a lesser degree Gclc[1].
MIND4-17 (0.1-2 μM; 24 hr) shows a concentration-dependent induction of NQO1 and GCLM proteins in both WT and HD mutant ST14A cells[1].
MIN4-17 (0.1-10 μM) reduces ROS levels and nitrogen intermediates production in microglia[1].
MIND4‐17 (2 mg/kg; intravitreal injection; once) activates Nrf2 signaling and attenuates retinal dysfunction by light damage in mice[2].
References:
[1]. Luisa Quinti, et al. SIRT2- and NRF2-Targeting Thiazole-Containing Compound with Therapeutic Activity in Huntington's Disease Models. Cell Chem Biol. 2016 Jul 21;23(7):849-861.
[2]. Nan Chen, et al. The Nrf2 activator MIND4-17 protects retinal ganglion cells from high glucose-induced oxidative injury. J Cell Physiol. 2020 Oct;235(10):7204-7213.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *